

Neeraj Y Saini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1165707/publications.pdf>

Version: 2024-02-01

65
papers

490
citations

759055

12
h-index

794469

19
g-index

65
all docs

65
docs citations

65
times ranked

831
citing authors

#	ARTICLE	IF	CITATIONS
1	A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma. <i>Blood</i> , 2022, 139, 1289-1301.	0.6	9
2	Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. <i>Leukemia and Lymphoma</i> , 2022, 63, 710-721.	0.6	8
3	Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). <i>Bone Marrow Transplantation</i> , 2022, 57, 51-56.	1.3	19
4	Impact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 307.e1-307.e8.	0.6	1
5	KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma. <i>Bone Marrow Transplantation</i> , 2022, 57, 1142-1149.	1.3	7
6	Haploidentical versus Matched Unrelated versus Matched Sibling Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 395.e1-395.e11.	0.6	6
7	Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma. <i>Blood Cancer Discovery</i> , 2022, 3, 385-393.	2.6	29
8	Real-world analysis of safety and efficacy of CAR T-cell therapy in patients with lymphoma with decreased renal function.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7536-7536.	0.8	1
9	Lenalidomide: Based maintenance after autologous hematopoietic stem cell transplant for patients with high-risk multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2022, 40, e20024-e20024.	0.8	0
10	Phase II study of umbilical cord blood-derived natural killer (CB-NK) cells with elotuzumab, lenalidomide, and high-dose melphalan followed by autologous stem cell transplantation (ASCT) for patients with high-risk multiple myeloma (HRMM).. <i>Journal of Clinical Oncology</i> , 2022, 40, 8009-8009.	0.8	2
11	Can we cure refractory Hodgkin's lymphoma with transplantation?. <i>Bone Marrow Transplantation</i> , 2021, 56, 278-281.	1.3	2
12	Safety of CAR T-cell therapy in kidney transplant recipients. <i>Blood</i> , 2021, 137, 2558-2562.	0.6	33
13	Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide-based maintenance therapy. <i>British Journal of Haematology</i> , 2021, 193, e23-e26.	1.2	3
14	Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 404.e1-404.e5.	0.6	3
15	Myeloablative Fractionated Busulfan With Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 913.e1-913.e12.	0.6	6
16	Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma. <i>Haematologica</i> , 2021, 106, 3211-3214.	1.7	13
17	Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allogeneic Transplantation. <i>Journal of Clinical Oncology</i> , 2021, 39, 2710-2719.	0.8	32
18	Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous Transplant. <i>Clinical Cancer Research</i> , 2021, 27, 5847-5856.	3.2	3

#	ARTICLE	IF	CITATIONS
19	Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites: A propensity score matched analysis. American Journal of Hematology, 2021, 96, E455-E457.	2.0	3
20	Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplantation and Cellular Therapy, 2021, 27, 1003.e1-1003.e13.	0.6	10
21	Optimizing Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Regimen: Results of Two Parallel Cohorts in a Phase 2 Prospective Clinical Trial. Blood, 2021, 138, 1802-1802.	0.6	0
22	A Prospective Phase I/II Trial to Jointly Optimize the Administration Schedule and Dose of Melphalan for Injection (Evomela) As a Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma. Blood, 2021, 138, 3941-3941.	0.6	0
23	Autologous Hematopoietic Stem Cell Transplantation for AL Amyloidosis Refractory to Induction Therapy. Blood, 2021, 138, 482-482.	0.6	2
24	Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis. Biology of Blood and Marrow Transplantation, 2020, 26, 665-671.	2.0	21
25	Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1077-1083.	2.0	4
26	Chimeric Antigen Receptor T-Cells in B-Acute Lymphoblastic Leukemia: State of the Art and Future Directions. Frontiers in Oncology, 2020, 10, 1594.	1.3	46
27	Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity. Blood Advances, 2020, 4, 1296-1306.	2.5	7
28	Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT. Blood Advances, 2020, 4, 47-54.	2.5	20
29	Update of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant (AuSCT) in Patients (Pts) with Multiple Myeloma (MM). Blood, 2020, 136, 46-47.	0.6	5
30	A Phase II Study of Pembrolizumab in Combination with Romidepsin Demonstrates Durable Responses in Relapsed or Refractory T-Cell Lymphoma (TCL). Blood, 2020, 136, 40-41.	0.6	15
31	Outcomes in Patients with AL (Light-Chain) Cardiac Amyloidosis. Blood, 2020, 136, 11-13.	0.6	0
32	PBSC Mobilization for Auto-HSCT in Myeloma: Growth Factors Vs Growth Factors + Chemotherapy. Blood, 2020, 136, 6-7.	0.6	0
33	Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with t(11;14) Undergoing Autologous Hematopoietic Stem Cell Transplantation. Blood, 2020, 136, 18-19.	0.6	0
34	Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma. Blood, 2020, 136, 22-22.	0.6	0
35	Factors Associated with the Improvement of Outcomes of High-Risk Relapsed Hodgkin Lymphoma (HL) Patients Receiving High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT): The MD Anderson Cancer Center Experience. Blood, 2020, 136, 17-18.	0.6	0
36	Gut Bacterial Diversity Associates with Efficacy of Anti-CD19 CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma. Blood, 2020, 136, 34-35.	0.6	1

#	ARTICLE	IF	CITATIONS
37	Nonmyeloablative Allogeneic Stem Cell Transplantation with or without Inotuzumab Ozogamicin for Lymphoid Malignancies. <i>Blood</i> , 2020, 136, 10-12.	0.6	0
38	Prognostic Impact of Beta 2 Microglobulin in Patients with Immunoglobulin Light-Chain Amyloidosis Undergoing Autologous Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 20-21.	0.6	0
39	Risk of Gvhd and Survival in Patients with Acute Leukemia Who Were Bridged to Allogeneic Stem Cell Transplantation (alloSCT) with Venetoclax- Based Therapy. <i>Blood</i> , 2020, 136, 13-14.	0.6	1
40	Outcomes of Patients with Multiple Myeloma Who Received VRD Induction, Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance. <i>Blood</i> , 2020, 136, 14-15.	0.6	0
41	Long-Term Survival for Myeloma after Autologous Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 23-24.	0.6	0
42	Autologous Stem Cell Transplantation for Angioimmunoblastic T-Cell Lymphoma. <i>Blood</i> , 2020, 136, 40-41.	0.6	0
43	African-Americans Multiple-Myeloma Patients Undergoing Upfront Autologous Stem Cell Transplant Have Similar Survival Outcomes Compared to Whites: A Propensity-Score Matched Analysis. <i>Blood</i> , 2020, 136, 9-10.	0.6	1
44	Survival Trends in Multiple Myeloma after Autologous Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 24-25.	0.6	1
45	Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation. <i>Blood Advances</i> , 2019, 3, 1661-1669.	2.5	21
46	Outcomes of autologous stem cell transplantation in Waldenström's macroglobulinemia. <i>Annals of Hematology</i> , 2019, 98, 2233-2235.	0.8	6
47	Autologous Stem Cell Transplantation for Multiple Myeloma: Growth Factor Matters. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e293-e297.	2.0	6
48	Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1340-1346.	2.0	7
49	Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis. <i>Clinical Cancer Research</i> , 2019, 25, 6781-6787.	3.2	10
50	Elderly do benefit from induction chemotherapy: High dose mitoxantrone-based ($\alpha\omega 5 + 1\hat{\epsilon}$) induction chemotherapy regimen in newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2019, 94, 209-215.	2.0	8
51	Melphalan-based autologous transplant in octogenarian multiple myeloma patients. <i>American Journal of Hematology</i> , 2019, 94, E2-E5.	2.0	5
52	Large granular lymphocytic leukemia-associated peripheral neuropathy. <i>Annals of Hematology</i> , 2018, 97, 1501-1504.	0.8	2
53	Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome. <i>American Journal of Hematology</i> , 2018, 94, E72-E74.	2.0	4
54	Rare gene fusion rearrangement SPTNB1-PDGFRB in an atypical myeloproliferative neoplasm. <i>Molecular Cytogenetics</i> , 2018, 11, 56.	0.4	1

#	ARTICLE	IF	CITATIONS
55	Hematopoietic Cell Transplant - Comorbidity Index (HCT-CI) Score Is a Useful Tool for Predicting Induction Mortality and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia Patients. <i>Blood</i> , 2018, 132, 1396-1396.	0.6	0
56	Impact of t(11;14) on the Outcome of Autologous Transplantation in Multiple Myeloma: A Matched-Pair Analysis. <i>Blood</i> , 2018, 132, 4607-4607.	0.6	0
57	Calcineurin inhibitor-free GVHD prophylaxis with sirolimus and mycophenolate mofetil combination. <i>Annals of Hematology</i> , 2017, 96, 1563-1568.	0.8	5
58	Novel immunomodulatory compounds in multiple myeloma. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 207-215.	1.9	11
59	Brugada-Type Electrocardiographic Changes Induced by Fever. <i>Circulation</i> , 2013, 127, 2145-2146.	1.6	14
60	HHV8-Negative Primary Effusion Lymphoma of B-Cell Lineage: Two Cases and a Comprehensive Review of the Literature. <i>Case Reports in Oncological Medicine</i> , 2013, 2013, 1-12.	0.2	24
61	Risk factors for the development of chemotherapy-related hospitalization (CRH) in patients treated with palliative intent: Results of a 9-year nested case control study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3-3.	0.8	4
62	Therapeutic strategies for the treatment of multiple myeloma. <i>Discovery Medicine</i> , 2013, 15, 251-8.	0.5	9
63	Hyperuricemic Renal Failure in Nonhematologic Solid Tumors: A Case Report and Review of the Literature. <i>Case Reports in Medicine</i> , 2012, 2012, 1-5.	0.3	12
64	The perils of not digging deep enough—uncovering a rare cause of acquired anemia. <i>American Journal of Hematology</i> , 2012, 87, 413-416.	2.0	8
65	Is routine computed tomographic scanning justified in the first week of persistent febrile neutropenia in children with malignancies?. <i>Pediatric Blood and Cancer</i> , 2011, 57, 620-624.	0.8	19